Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-031145
Filing Date
2025-03-03
Accepted
2025-03-03 18:30:03
Documents
1
Period of Report
2025-03-03

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3880
  Complete submission text file 0000950170-25-031145.txt   5356
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Issuer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS, SUITE 230 WATERTOWN MA 02472
Business Address
Mainolfi Nello (Reporting) CIK: 0001821189 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39460 | Film No.: 25700576